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Vulvar lichen sclerosus and lichen planus are T-cell–mediated chronic skin disorders. Although autoimmunity
has been suggested, the exact pathogenesis of these disorders is still unknown. Therefore, the aim of the
current study was to investigate the molecular and immunological mechanisms critical to the pathogenesis of
vulvar lichen sclerosus and lichen planus. By using gene expression profiling and real-time RT-PCR experiments,
we demonstrated a significantly increased expression of the pro-inflammatory cytokines (IFNg, CXCR3, CXCL9,
CXCL10, CXCL11, CCR5, CCL4, and CCL5) specific for a Th1 IFNg-induced immune response. In addition, BIC/
microRNA-155 (miR-155)—a microRNA involved in regulation of the immune response—was significantly
upregulated in lichen sclerosus and lichen planus (9.5- and 17.7-fold change, respectively). Immunohistochem-
istry showed a significant T-cell response, with pronounced dermal infiltrates of CD4þ , CD8þ , and FOXP3þ
cells. In conclusion, these data demonstrate an autoimmune phenotype in vulvar lichen sclerosus and lichen
planus, characterized by increased levels of Th1-specific cytokines, a dense T-cell infiltrate, and enhanced BIC/
miR-155 expression.
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INTRODUCTION
Vulvar lichen sclerosus (LS) and lichen planus (LP) are both
chronic inflammatory skin disorders that have a negative
impact on the quality of life and may proceed to malignant
disease (McPherson and Cooper, 2010).
LS can affect any part of the skin, but it is most frequently
seen in the anogenital area. Although it can occur at all ages,
even among children, LS is most common in the fifth to sixth
decade of life (Powell and Wojnarowska, 1999; Tasker and
Wojnarowska, 2003). Women with vulvar LS often present
with severe pruritus and soreness of the vulvar and perianal
area (Powell and Wojnarowska, 1999; Tasker and Wojnar-
owska, 2003; Val and Almeida, 2005). Typically, lesions
appear as a figure-of-eight pattern around the vulva and anus,
with white atrophic lesions or hyperkeratosis. In advanced
stages, there is destruction of the vulvar anatomy, character-
ized by resorption of the labia minora, narrowing of the
introitus, and a buried clitoris (Powell and Wojnarowska,
1999).
LP also generally develops in the fifth to sixth decade of
life (Lewis, 1998; Goldstein and Metz, 2005). In contrast to
LS, the mucosa can be involved in LP, resulting in vaginal and
oral lesions (Kirtschig et al., 2005b; Santegoets et al., 2010).
Patients usually present with vulvar soreness, pruritus,
burning, dyspareunia, and/or vaginal discharge. Erosive
lesions, with denuded epithelium associated with typical
white Wickham’s striae, can arise at the vulvar or vaginal
mucosa, and alterations of normal vulvar architecture may
occur. In severe cases, adhesions and stenosis can lead to
complete obliteration of the vagina (Lewis, 1998; Goldstein
and Metz, 2005; Kirtschig et al., 2005b).
Histologically, both the disorders are characterized by a
band-like lymphocytic infiltrate and by a thinned epidermis
with vacuolar changes in the basal layer. In long-standing,
classic LS, the lymphocytic infiltrate is located under a band
of homogenized collagen below the dermoepidermal junc-
tion, whereas in LP this infiltrate is situated directly beneath
the epidermis (McPherson and Cooper, 2010). However,
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histological evaluation of LS and LP can be difficult, because
especially the first phase of LS can show histological overlap
with LP (Marren et al., 1994).
Local application of ultrapotent corticosteroids is still the
treatment of choice for both the disorders. If corticosteroids
are not helpful in patients with LP, the use of topical
calcineurin inhibitors (tacrolimus or pimecrolimus) may be
considered (Goldstein et al., 2009). However, all these
treatment options only reduce symptoms and generally do
not stop disease progression (McPherson and Cooper, 2010).
This illustrates the importance of new treatment strategies.
One example of such a new treatment option is photo-
dynamic therapy. The possible antisclerotic and anti-inflam-
matory effect of photodynamic therapy might be induced by
the reduction of transforming growth factor (TGF)-b1 and/or
the increase of IL-10 after photodynamic therapy (Byun et al.,
2011). As progression to vulvar squamous cell carcinoma has
been reported for LS and LP, lifelong follow-up of these
patients is indicated (McPherson and Cooper, 2010).
The etiology of these disorders has not yet been
elucidated. Various studies have suggested different etiologi-
cal factors. Cases of familial LS and LP have been reported
and an association with HLA class II antigens has been found,
suggesting a genetic background (Marren et al., 1995; Powell
et al., 2000; Setterfield et al., 2006). Other studies have
suggested a role for local factors and infectious agents, such
as an infection with Borrelia burgdorferi, human papilloma-
virus, or hepatitis C virus. However, the results of these
studies are inconclusive, and none of these agents has been
proven to be pathogenetic (Kirtschig et al., 2005a; van de
Nieuwenhof et al., 2008; Zollinger et al., 2010). Current
opinion suggests an autoimmune pathogenesis for both
disorders, as patients with LS and LP are more frequently
diagnosed with autoimmune disorders such as vitiligo and
thyroid disease, and the presence of autoantibodies—for
example, antibodies to extracellular matrix protein 1 in
patients with LS—has been observed (Oyama et al., 2003;
Cooper et al., 2008).
In summary, as it is not clear what causes LS or LP, the aim
of this study was to elucidate the molecular mechanisms
involved in the pathogenesis of vulvar LS and LP.
RESULTS
Identification of differentially expressed genes in LS and LP
To study signaling pathways involved in both disorders, we
conducted gene expression arrays. Using significant analysis
of microarrays, we found 6,643 differentially expressed probe
sets between LS and controls, 7,354 between LP and controls,
and 623 between LS and LP (Figure 1). The number of
differentially expressed genes between LS and LP was only
10% of the number of genes differentially expressed between
LP and controls or between LS and controls (the complete list
of differentially expressed genes can be obtained from
Supplementary Table S1 online).
By using Ingenuity Pathway Analysis, we identified
biological functions that were significantly regulated in LS
and LP as compared with control samples. The following
biological functions were found (Po0.001): (1) antigen
presentation, (2) cell-mediated immune response, (3) humor-
al immune response, and (4) inflammatory response (Supple-
mentary Figure S1 online). High regulation of these biological
functions is caused by the fact that most differentially
expressed genes between LS/LP and control tissues are
involved in pathways related to the immune response. This
result was also found by Edmonds et al. (2011), who studied
gene expression profiling in male genital LS.
To investigate the immune response in more detail, we
used the KEGG cytokine–cytokine receptor pathway
(www.genome.jp/kegg/) as a background for our own
immune signaling data. Many cytokines were upregulated
in LS and LP (Figure 2). For most genes, this upregulation was
more pronounced in LP than in LS. By studying those
cytokines in more detail, we focused on well-known pro-
inflammatory and anti-inflammatory cytokines (Dinarello,
2000). Of the pro-inflammatory cytokines, we found upre-
gulation of IL1, IL6 (only in LP), IL7, IL15, IFNg, and TNFa.
For most of the anti-inflammatory cytokines, no modulation
was found (for example, for IL4 and IL13), and only slight
upregulation of TGFb1 (only in LP) and TGFb2 (only in LS)
was found. Interestingly, IL11, also known as an anti-
inflammatory cytokine, was downregulated in LS and LP. In
summary, significantly more pro-inflammatory cytokines
were highly expressed in LS and LP, which is regarded as
an indication for a cellular T-helper type 1 (Th1) response
(Szabo et al., 2003).
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Figure 1. Gene expression profiles of lichen sclerosus (LS) and lichen planus
(LP). Unsupervised clustering of expression profiles from 18 control, 5 LP, and
10 LS samples. (a) A total of 6,643 genes were differentially regulated in LS
versus control; (b) 7,354 genes were differentially regulated in LP versus
control; (c) 623 genes were differentially regulated in LP versus LS.
Each row represents one gene (red: upregulated; blue: downregulated;
see color figure online) and each column represents one expression profile
from one tissue sample.
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IFNg is one of the key factors in Th1 response, and its
mRNA was strongly upregulated in LS and LP (3.5- and 7.8-
fold, respectively, Figure 2). It is produced by T-helper cells
(CD4þ T cells), which are characterized by chemokine
receptors CXCR3 and CCR5 (Sallusto and Lanzavecchia,
2000). As shown later (Figure 4), in the dermis significantly
higher levels of CD4þ T cells were seen in LS and LP, and as
expected both CXCR3 and CCR5 were highly expressed in
both disorders. Besides this strong expression of CXCR3 and
CCR5, their activating ligands CXCL9, CXCL10, CXCL11 and
CCL3, CCL4, respectively, were also strongly upregulated.
These results indicate that the infiltrate of CD4þ T cells
seems to be involved in the production of significant amounts
of IFNg, CXCL9, CXCL10, CXCL11, CCL3, and CCL4, thus
further stimulating a cellular Th1 response in LS and LP.
Other stimulatory factors for the production of Th1 cytokines
and consequently for the differentiation of T cells to the Th1
phenotype are cytokines of the IL-1 family: namely, IL1a,
IL1b, and IL18 (Figure 2, the IL-1 family is indicated with a
black box). We found upregulation of IL1a and the IL18
receptor in LS and LP and upregulation of IL1b in LP. To
activate these inflammatory cytokines, caspase 1 is neces-
sary. As expected, caspase 1 was significantly upregulated in
LS (1.8-fold) and in LP (2.0-fold).
All the observations described above suggest a strong Th1
response. However, to investigate the potential role of Th2
and Th17 after Th1, we carried out real-time RT-PCR on
important regulators of these responses. A clear and
pronounced upregulation of IFNg and CXCL10 was con-
firmed, indicating a Th1 response, whereas we found no
significant regulation of key factors in the Th2 (CCR3, IL4)
and Th17 (IL17A, IL17F, IL22R) response (Figure 3a).
Another important finding concerning the immune re-
sponse was the strong upregulation of BIC, a gene that
encodes for microRNA-155 (miR-155). MiR-155 has an
important role in regulating homeostasis of the immune
system. It regulates production of cytokines, chemokines, and
transcription factors, but has also been shown to promote
T-cell–dependent autoimmune inflammation (Rodriguez et al.,
2007; O’Connell et al., 2010). We found strong upregulation
of BIC/miR-155 in LS (9.5-fold) and LP (17.7-fold) compared
with controls (Figure 3b). This upregulation was confirmed by
TaqMan RT-PCR (LS: 8.5-fold; and LP: 17.5-fold, Figure 3a). In
contrast, no differential gene expression of BIC/miR-155 was
observed between controls and usual-type vulvar intraepithe-
lial neoplasia (uVIN) samples, a vulvar disease with a strong
lymphocytic dermal infiltrate (Figure 3b).
Immune cell counts in LS and LP
To document the composition of the cellular infiltrate, the
presence of CD4þ T cells, CD8þ T cells, FOXP3þ regulatory
T (Treg) cells, CD1aþ dendritic cells/Langerhans cells, and
Figure 2. The cytokine–cytokine receptor pathway in lichen sclerosus (LS) and lichen planus (LP). The cytokine–cytokine receptor scheme from the
KEGG database (www.genome.jp/kegg/) was used to overlay gene expression values in LS and LP compared with controls. Each box represents one gene:
the color represents the fold change expression value in LP (left side) and LS (right side) (see color figure online). Black boxes mark (1) CXCR3 and CCR5 and
their ligands, (2) IFNg, and (3) the IL-1 family.
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CD19þ B cells was assessed. In LS, no differences in immune
cell counts were observed in the epidermis compared with
controls. However, in the dermis, cell counts for CD8þ T
cells and FOXP3þ Treg cells were significantly higher than in
controls (Po0.001 and P¼0.013, respectively, Figure 4 and
Supplementary Table S2 online). In contrast, CD1aþ cells
were significantly decreased in the dermis (P¼0.008,
Supplementary Table S2 online).
In the epidermis of LP, FOXP3þ Treg cells were
significantly increased compared with controls (P¼0.024),
and no differences were observed for the other immune cells.
In the dermis, however, a significant increase in CD4þ T
cells, CD8þ T cells, FOXP3þ Treg cells, and CD19þ B cells
was observed in LP in comparison with controls (Figure 4 and
Supplementary Table S2 online). Similar to differences in
gene expression levels, differences in immune cell counts
were more pronounced in LP than in LS.
DISCUSSION
Recent publications indicate that LS and LP may be
autoimmune disorders. First, similar to autoimmune diseases,
genital LS and LP are more common in women than in men
(Powell and Wojnarowska, 1999; Moyal-Barracco and
Edwards, 2004). Second, patients with LS and LP are more
frequently diagnosed with other autoimmune disorders such
as vitiligo and thyroid disease, and patients with LP show
more frequently circulating autoantibodies (Cooper et al.,
2008). In addition, the presence of autoreactive T cells
against basement membrane zone components has been
observed in LS and LP (Oyama et al., 2003; Howard et al.,
2004; Cooper et al., 2005; Baldo et al., 2010). Finally, an
association of LS with HLA class II antigen DQ7 and of LP
with HLA DRB1*0201 has been demonstrated (Marren et al.,
1995; Powell et al., 2000; Setterfield et al., 2006).
From the abovementioned, it can be hypothesized that
aberrant immune signaling has a role in the pathogenesis of
LS and LP, although the exact molecular mechanisms that
lead to these immunological changes have not yet been
clarified. Here we will discuss our main findings, which
further corroborate that autoinflammatory mechanisms are
the basis of both LS and LP.
LS and LP are characterized by a strong Th1 response
In both disorders, the lymphocytic infiltrate contained
primarily T cells. In LS patients, a significant increase in
CD8þ T cells and Treg cells was observed, whereas CD4þ
T-cell counts in LS were not significantly increased (P¼ 0.07).
For LP, a more pronounced increase for all immune cell
counts was observed, with significantly increased T-cell and
B-cell counts. These data are in agreement with published
investigations describing dense T-cell infiltrates in LS and LP
(Regauer, 2005; Farrell et al., 2006; Wenzel et al., 2006,
2007).
To investigate whether these T cells are involved in a Th1
or Th2 response, we studied the different chemokine
receptors. Th1 cells are characterized by the expression of
CXCR3 and CCR5, whereas Th2 cells express CCR3 and
CCR4 (Sallusto and Lanzavecchia, 2000). We found high
levels of the CXCR3 and CCR5 in LS and LP and no
expression of CCR3 and CCR4, indicating an infiltrate of Th1
cells. Although the role of Th1 response in autoimmune
disorders is not completely understood, it seems to have an
important role in the induction, maintenance, and exacerba-
tion of chronic inflammation. This inflammation is controlled
by the presence of Th1 cells, which produce IFNg. High
levels of IFNg will attract and stimulate different immune and
epithelial cells. In reaction to this, these cells will produce
ligands for the CXCR3 and CCR5 receptors (namely,
cytokines CXCL9, CXCL10, CXCL11, CCL3, and CCL4;
Figure 2), thereby attracting more Th1 cells to the site of
inflammation. As a result, the Th1 response will be
maintained and intensified, resulting in chronic inflammation
(Liu et al., 2005). The important role for the Th1 phenotype in
LS and LP was further illustrated by the upregulation of IL1a
and caspase 1. The binding of caspase 1 to cytokines of the
IL-1 family results in activation of the inflammatory processes
and suggests the involvement of inflammasomes.
The role of the above-described cytokines in relation to
autoimmunity has previously been investigated and reviewed
(Liu et al., 2005; Charo and Ransohoff, 2006; Rotondi et al.,
2007). In various autoinflammatory and autoimmune dis-
orders, such as multiple sclerosis (Balashov et al., 1999;
Sorensen et al., 1999, 2002), rheumatoid arthritis (Ruth et al.,
2001), systemic lupus erythematosus (Wenzel et al., 2005),
Graves’ disease (Aust et al., 2002; Romagnani et al., 2002),
type 1 diabetes mellitus (Shimada et al., 2009), and vitiligo
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Figure 3. Real-time RT-PCR results. (a) Differences in gene expression
are visualized for key factors in the T-helper type 1 (Th1), Th2, and Th17
response and for validation of microRNA-155 (miR-155) expression by
TaqMan RT-PCR (control n¼ 5, lichen sclerosus (LS) n¼ 5, and lichen
planus (LP) n¼5). 1No significant difference was found on microarray data,
and therefore no real-time RT-PCR was carried out. (b) Gene expression
of BIC/miR-155 in controls (n¼ 14), LS (n¼8), LP (n¼ 5), and usual-type
vulvar intraepithelial neoplasia (uVIN, n¼9).
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(Gregg et al., 2010), high levels of CXCR3 and its ligands
have been described (Table 1). In Figure 5, a schematic
representation of this feedforward autoinflammatory process
is shown, which, according to our data, has a major role in
the autoinflammatory pathogenesis of LS and LP. Further-
more, the upregulation of caspase 1 and IL1a also suggests
a role for inflammosome activity in both disorders, as
previously described for various autoimmune diseases (Shaw
et al., 2011). Future investigations should focus on the role of
inflammosomes in LS and LP.
In addition to increased immune cell counts and expres-
sion of pro-inflammatory cytokines, we also observed an
increased expression of miR-155. As indicated in Figure 5,
elevated expression of miR-155 may be a primary molecular
event that initiates the activation of immune cells. This
concept will be discussed in the next section.
MiR-155 is profoundly upregulated in LS and LP
MicroRNAs are small endogenous noncoding RNAs that post-
transcriptionally regulate gene expression by base-pairing to
imperfect complementary target sites on the RNA, or by
partially blocking translation (Bartel, 2004, 2009). It is known
that miR-155 has a critical role in regulating homeostasis of
the immune system. It regulates production of cytokines,
chemokines, and transcription factors, and it is induced by
endotoxins via toll-like receptor signaling (O’Connell et al.,
2007; Rodriguez et al., 2007; Thai et al., 2007; Tili et al.,
2007). Furthermore, miR-155 is expressed in several types of
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Table 1. Expression of cytokines and miR-155 in
different autoinflammatory/autoimmune disorders
according to the literature
Disorder Cytokine profile
Multiple sclerosis (Balashov et al., 1999;
Sorensen et al., 1999, 2002; Junker et al., 2009)
CXCR3m, CXCL9m,
CXCL10m, IFNgm,
miR-155m
Rheumatoid arthritis (Ruth et al., 2001;
Stanczyk et al., 2008; Bluml et al., 2011)
CXCR3m, CXCL9m,
CXCL10m, IFNgm,
miR-155m
Systemic lupus erythematosus (Wenzel
et al., 2005; Divekar et al., 2011)
CXCR3m, CXCL9m,
CXCL10m, IFNgm,
miR-155m
Graves’ disease (Aust et al., 2002;
Romagnani et al., 2002)
CXCR3m, CXCL9m,
CXCL10m, IFNgm
Type 1 diabetes mellitus
(Shimada et al., 2009)
CXCR3m, CXCL9m,
CXCL10m, IFNgm
Vitiligo (Gregg et al., 2010) CXCR3m, IFNgm
Abbreviation: miR-155, microRNA-155.
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activated immune cells, such as macrophages, dendritic
cells, B cells, and T cells, and promotes T-cell differentiation
toward Th1 (Haasch et al., 2002; van den Berg et al., 2003;
Eis et al., 2005; O’Connell et al., 2007; Rodriguez et al.,
2007).
On the basis of this, it can be hypothesized that increased
expression of miR-155 in LS and LP originates from the dense
T-cell infiltrate in both disorders. However, we did not
observe overexpression of BIC/miR-155 in uVIN, a vulvar
disease that also has a strong dermal lymphocytic infiltrate
(Figure 3b). A possible explanation for the difference in
expression of miR-155 in LS/LP and in uVIN could be that the
lymphocytic infiltrate in LS and LP primarily consists of
activated T cells, whereas in uVIN the T-cell response seems
to be ineffective as these T cells are unable to clear the
human papillomavirus, the underlying cause of uVIN (Terlou
et al., 2010).
A role for miR-155 in autoimmune diseases has been
demonstrated recently, and increased expression was
observed in different autoinflammatory and autoimmune
diseases, such as multiple sclerosis and rheumatoid arthritis
(Table 1; Stanczyk et al., 2008; Junker et al., 2009; O’Connell
et al., 2010; Bluml et al., 2011; Divekar et al., 2011).
One important mechanism inducing autoimmunity is loss of
immune tolerance. Normally, unwanted immune responses
are controlled by the suppressive function of Treg cells,
which are known to have a critical role in the maintenance
of immune tolerance. In a mouse model studying systemic
lupus erythematosus, it was observed that artificially
enhanced miR-155 expression resulted in an altered Treg
cell phenotype and thereby in a reduced suppressive func-
tion of Treg cells (despite an increase in Treg cell counts)
(Divekar et al., 2011). In addition, another study showed
that increased miR-155 levels in CD4þ T cells resulted in
reduced Treg-cell–mediated suppression (Stahl et al., 2009).
For LS and LP, a similar mechanism may be at work: because
of enhanced miR-155 levels, the observed increased numbers
of Treg cells may not fully affect CD4þ T cells, thus resulting
in impaired immune tolerance toward self-antigens causing
autoimmunity.
Immune cells
Endothelial cells
Epithelial cells
Figure 5. Hypothesized mechanism of pathogenesis of lichen sclerosus (LS) and lichen planus (LP). MicroRNA-155 (miR-155) is strongly upregulated in LS
and LP and possibly affects regulatory T (Treg) cell–mediated suppression of CD4þ T cells by affecting the suppressive function of Treg cells and by reducing
the susceptibility of CD4þ T cells for Treg cell–mediated suppression. The T-cell response is skewed to T-helper type 1 (Th1). Upregulation of CXCR3 and
CCR5 (Th1 receptors) results in increased production of IFNg, which attracts different dendritic, epithelial, and endothelial cells. In response, these cells
will produce high amounts of CXCL9, CXCL10, and CXCL11, and CCL3 and CCL4, which in turn intensify and maintain the Th 1 response. Correlations
between IFNg and these ligands are shown on the right (Spearman’s correlation coefficient). Blue: controls (n¼ 18); red: LS (n¼10); orange: LP (n¼5); see color
figure online.
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LS and LP have profound characteristics of an autoimmune
disorder
Summarizing our data, we demonstrate high levels of BIC/
miR-155 and increased gene expression of pro-inflammatory
cytokines involved in autoimmunity, with an important role
for CXCR3 and CCR5 and their ligands, resulting in a dense
infiltration of T cells. Overall, these observations were more
pronounced in LP than in LS. In addition, Cooper et al (2008)
recently found significantly higher levels of autoantibodies in
52/126 (41%) women with LP and in 39/190 (21%) women
with LS compared with controls. We also found autoanti-
bodies in a high percentage of patients with LP (32%) and
LS (14%, data not shown). Taken together with previous
data about associations with HLA-DR, other autoimmune
diseases, and demonstration of autoreactive T cells, an
autoimmunological basis for LS and LP seems likely. Future
studies should focus on the role of miR-155 and the immune
response in these disorders, which may be a focus for more
targeted therapies.
MATERIALS AND METHODS
Patient samples
Fresh, frozen, and formalin-fixed tissues of patients with a clini-
cally and histologically confirmed diagnosis of LS and LP were
selected from the anonymous pathology archive of the Erasmus
University Medical Center. Control samples were obtained from
healthy women who underwent elective vulvar surgery for cosmetic
reasons.
Fresh tissues were directly frozen in liquid nitrogen after
collection and were stored at 80 1C until further analysis.
Cryosections of 10mm were obtained, and the first and tenth
sections in a series of 10 were stained to assess tissue morphology.
The remaining sections were used to isolate total RNA using Trizol
(Invitrogen, Life Technologies, Philadelphia, PA), and quality and
quantity were assessed using the Agilent 2100 Bioanalyzer (Agilent,
Palo Alto, CA).
RNA was isolated from 14 control samples, 12 LS, and 11 LP
samples. From these samples, we selected 14 control, 8 LS, and 5 LP
samples for the microarray experiment. To confirm microarray data,
we carried out RT-PCR experiments using RNA of four LS and two LP
of the microarray samples, combined with RNA of other samples
(four LS and six LP).
For immunohistochemistry, we selected cryosections and paraffin
sections of LS (n¼ 16), LP (n¼ 9), and control samples (n¼ 10).
Once more, to confirm microarray data, these samples were other
than the ones used for the microarray experiments.
The medical ethics committee of the Erasmus University Medical
Center approved our study design and the protocol was compliant
with the Declaration of Helsinki Principles.
Microarray and microarray data analysis
Affymetrix U133plus2 GeneChips were used to obtain gene
expression profiles of 8 LS (median age 58 years, range 22–76),
5 LP (median age 59 years, range 51–78), and 14 control samples
(median age 40 years, range 17–54). In addition, nine samples of
patients with uVIN (median age 39, range 33–48), a vulvar disease
with a strong lymphocytic dermal infiltrate, were used for the
analysis of BIC/miR-155 gene expression. Isolation of RNA, staining,
washing, and scanning procedures were carried out as described
by the manufacturer (Affymetrix, Santa Clara, CA) (Santegoets et al.,
2007). Raw (.CEL files) and normalized microarray data have been
deposited in the GEO repository at NCBI under accession number
GSE5563.
Differentially expressed genes were identified by using signifi-
cant analysis of microarrays. A false discovery rate less than 1%
was considered statistically significant. Using OmniViz software
version 3.8 (Maynard, MA), hierarchical clustering of differentially
expressed genes was carried out.
Ontological analysis, using Ingenuity Pathway software (Ingenu-
ity Systems, www.ingenuity.com), was used to assess the functional
relevance of the observed differences in gene expression profiles.
Quantitative real-time RT-PCR
IFNc, IL17A, IL17F, IL22RA1, and CXCL10. Validation of the
expression of these genes was carried out in eight LS (of which four
were also used for microarray), eight LP (of which two were used for
microarray), and eight control samples in duplicate using real-time
quantitative RT-PCR (38 cycles, for 15 seconds at 95 1C, for
30 seconds at 59–62 1C, and for 1minute at 72 1C) using the Opticon
I (Applied Biosystems, Foster City, CA) and SYBR Green ITM
(Applied Biosystems). The cDNA samples (10 ng each) were
amplified with gene-specific primer pairs (0.5 mM) in a total volume
of 25 ml including 12.5ml SYBR Green PCR master mix (Applied
Biosystems). The housekeeping gene b-actin was used for normal-
ization, and all used PCR primers were intron spanning. The used
primer sequences can be obtained from Supplementary Table S3
online.
The relative fold increase of real-time RT-PCR results was
determined by the 2DDCt method (Livak and Schmittgen, 2001),
using the average expression of the housekeeping gene (b-actin) as
the control.
MicroRNA-155. Validation of the expression of miR-155 was
carried out using a two-step TaqMan RT-PCR assay (Applied
Biosystems) according to the manufacturer’s protocols in five LS,
five LP, and five control samples. The TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems) was used for the preparation
of cDNA; 10 ng of total RNA was used per 15 ml RT reaction. Reverse
transcription was carried out in a PTC-200 Peltier Thermal Cycler
(MJ Research, Biozym, Landgraaf, Belgium) for 30minutes at 16 1C,
for 30minutes at 42 1C, for 5minutes at 85 1C, and then held at 4 1C.
The RT products were subsequently amplified with sequence-specific
human miRNA primers using the Applied Biosystems 7900HT Real-
Time PCR system. The reactions were incubated in duplicate in a
96-well plate at 95 1C for 10minutes, followed by 40 cycles at 95 1C
for 15 seconds and at 60 1C for 1minute. Amplification signals were
computed with SDS v.2.3 software (Applied Biosystems). The fold
increase of miR-155 compared with control was determined by the
2DDCt method (Livak and Schmittgen, 2001), using the average
expression of two endogenous controls, RNU44 and RNU48.
Immunohistochemistry
Immunohistochemical staining was carried out on 6 mm-thick frozen
tissue sections. The following markers were used: CD4, marker for
T-helper cells (MT.310; Dako, Glostrup, Denmark); CD8, marker
for cytotoxic T cells (DK25; Dako); FOXP3, marker for Treg
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(EBioscience, Hatfield, UK); and CD19, marker for B cells (Beckman
Coulter, Brea, CA), in dilutions of 1:50, 1:50, 1:50, and 1:25,
respectively. Staining was carried out as described previously (van
Seters et al., 2008).
For identification of immature dendritic cells/Langerhans cells,
staining for CD1a (clone O10, Immunotech, Marseille, France) in a
dilution of 1:10 was carried out on paraffin-embedded tissue
sections as described earlier (Terlou et al., 2010).
Stained cells were counted throughout the epidermal thickness
and 100 mm deep into the dermis in a blinded session. Because the
cell infiltrate in LS tissue is localized in the mid-dermis below a
subepidermal sclerotic zone, LS tissues were counted 100mm deep
into the mid-dermal infiltrate. After measuring the total area of the
epidermis and dermis by using the Leica Image Analysis System
(Leica Microsystems B.V., Rijswijk, The Netherlands), the number of
cells per square millimeter was calculated for each layer separately.
Statistical analysis
Data were analyzed using the SPSS 17.0 software package (SPSS,
Chicago, IL) for Windows. Immunohistochemistry and PCR data
were analyzed using the nonparametric Kruskal–Wallis test and the
Mann–Whitney test for independent samples. Correlation studies
were conducted using the nonparametric Spearman’s correlation
coefficient. A two-tailed P-value of Po0.05 was chosen to represent
statistical significance.
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